DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insights, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the EGFR Non-Small Cell Lung Cancer pipeline drug profiles, including EGFR Non-Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the EGFR Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the EGFR Non-Small Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, EGFR Non-Small Cell Lung Cancer clinical trials studies, EGFR Non-Small Cell Lung Cancer NDA approvals (if any), and product development activities comprising the technology, EGFR Non-Small Cell Lung Cancer collaborations, licensing, EGFR Non-Small Cell Lung Cancer mergers and acquisition, funding, designations and other product-related details.
Key takeaways from the EGFR Non-Small Cell Lung Cancer Pipeline Report
- DelveInsight’s EGFR Non-Small Cell Lung Cancer pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for EGFR Non-Small Cell Lung Cancer treatment.
- The leading EGFR Non-Small Cell Lung Cancer Companies includes Dizal Pharmaceuticals, Novartis Pharmaceuticals, AstraZeneca, Betta Pharmaceuticals Co., Ltd., Hangzhou ACEA Pharmaceutical Research, G1 Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Takeda, Janssen Research & Development LLC, Sinocelltech Ltd., Allist Pharmaceuticals, Inc., and others.
- Promising EGFR Non-Small Cell Lung Cancer Pipeline Therapies includes AZD3759, AZD9291, Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration), Naquotinib, Midazolam, Dacomitinib, and others.
- The EGFR Non-Small Cell Lung Cancer companies and academics are working to assess challenges and seek opportunities that could influence EGFR Non-Small Cell Lung Cancer R&D. The EGFR Non-Small Cell Lung Cancer pipeline therapies under development are focused on novel approaches to treat/improve EGFR Non-Small Cell Lung Cancer.
To explore more information on the latest breakthroughs in the EGFR Non-Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ EGFR Non-Small Cell Lung Cancer Pipeline Outlook
EGFR Non-Small Cell Lung Cancer Overview
Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.
Latest Developmental Activities or News of the EGFR Non-Small Cell Lung Cancer Treatment Landscape
- Dizal Pharmaceuticals is conducting a phase I/II, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics and anti-tumor efficacy of DZD9008 in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation.
- Novartis is conducting a phase I/II, multicenter, open-label study of EGFRmut-TKI EGF816, administered orally in adult patients with EGFRmut solid malignancies. This study will estimate the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (Phase l part) of EGF816 and to investigate the anti-tumor activity of EGF816 (Phase II part).
For further information, refer to the detailed EGFR Non-Small Cell Lung Cancer Unmet Needs, EGFR Non-Small Cell Lung Cancer Market Drivers, and EGFR Non-Small Cell Lung Cancer Market Barriers, click here for EGFR Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis
EGFR Non-Small Cell Lung Cancer Emerging Drugs Profile
- DZD9008: Dizal Pharmaceuticals
DZD9008 is an oral, potent, irreversible, wild type-selective EGFR TKI against EGFR or HER2 Exon20ins and other mutations. The present study shows anti-tumor activity of DZD9008 in tumor cell lines and xenograft models. Dizal Pharmaceuticals is conducting a phase I/II, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics and anti-tumor efficacy of DZD9008 in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation. This study includes dose escalation (Part A) and dose expansion (Part B). This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
- Nazartinib (EGF816) – Novartis Pharmaceuticals
EGF816 is an orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGF816 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.
EGFR Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
There are approx. 30+ key companies which are developing the therapies for EGFR Non-Small Cell Lung Cancer. The companies which have their EGFR Non-Small Cell Lung Cancer drug candidates in the advanced stage, i.e. phase III and Phase II include, AstraZeneca, Betta Pharmaceuticals, Millennium Pharmaceuticals, Takeda etc.
Request a sample and discover the recent advances in EGFR Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ EGFR Non-Small Cell Lung Cancer Treatment Landscape
Scope of the EGFR Non-Small Cell Lung Cancer Pipeline Report
- Coverage- Global
- EGFR Non-Small Cell Lung Cancer Companies- Dizal Pharmaceuticals, Novartis Pharmaceuticals, AstraZeneca, Betta Pharmaceuticals Co., Ltd., Hangzhou ACEA Pharmaceutical Research, G1 Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Takeda, Janssen Research & Development LLC, Sinocelltech Ltd., Allist Pharmaceuticals, Inc., and others.
- EGFR Non-Small Cell Lung Cancer Pipeline Therapies includes AZD3759, AZD9291, Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration), Naquotinib, Midazolam, Dacomitinib, and others.
- EGFR Non-Small Cell Lung Cancer Segmentation: Product Type, Molecule Type, Route of Administration, and Mechanism of Action
Dive deep into rich insights for drugs for EGFR Non-Small Cell Lung Cancer Market Drivers and EGFR Non-Small Cell Lung Cancer Market Barriers, click here @ EGFR Non-Small Cell Lung Cancer Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- EGFR Non-Small Cell Lung Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- EGFR Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- EGFR Non-Small Cell Lung Cancer Collaboration Deals
- Late Stage Products (Phase III)
- Mobocertinib (TAK 788): ARIAD Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II/III)
- AZD3759: AstraZeneca
- Early Stage Products (Phase I/II)
- DZD9008: Dizal Pharmaceuticals
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- EGFRm inhibitors: HitGen
- Drug profiles in the detailed report…..
- Inactive Products
- EGFR Non-Small Cell Lung Cancer Key Companies
- EGFR Non-Small Cell Lung Cancer Key Products
- EGFR Non-Small Cell Lung Cancer- Unmet Needs
- EGFR Non-Small Cell Lung Cancer- Market Drivers and Barriers
- EGFR Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
- EGFR Non-Small Cell Lung Cancer Analyst Views
- EGFR Non-Small Cell Lung Cancer Key Companies
- Appendix
Got Queries? Find out the related information on EGFR Non-Small Cell Lung Cancer Mergers and acquisitions, EGFR Non-Small Cell Lung Cancer Licensing Activities @ EGFR Non-Small Cell Lung Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services